We're are delighted to announce that the new CMV DDI Manager has been added to our suite of leading DDI tools. It contains DDI Management recommendations for 7 CMV agents and approx. 1,000 co-medications.

Patients diagnosed with cytomegalovirus (CMV) disease often have multiple comorbidities and are immunosuppressed, with polypharmacy being common.

Adding CMV treatment to already existing polypharmacy increases the risk of drug-drug interactions (DDIs).

To counteract this risk, we announce the new CMV DDI Manager– a cutting-edge tool developed in partnership with leading experts in the field.

The novel anti-CMV agents letermovir and maribavir are also included in the new CMV DDI Manager. Both drugs have demonstrated clinical benefit in the prevention or treatment, respectively, of CMV infection in allogeneic haemopoietic stem cell transplant or solid organ transplant recipients. Letermovir and maribavir can be perpetrators and victims of drug-drug interactions.

On April 28 at ECCMID in Barcelona, Laura Nijboer will be present with a poster about the management of drug-drug interactions with letermovir and maribavir DDIs with letermovir and maribavir. You are welcome to discuss this topic!